Oncology – Urological
Summary: German evidence-based guidelines on focal therapy in localized prostate cancer.
17 Mar, 2022 | 08:47h | UTC
Cohort Study: adjuvant vs. early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer.
17 Mar, 2022 | 08:09h | UTC
RCT: Observation vs. screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases.
16 Mar, 2022 | 08:26h | UTC
Commentary on Twitter
In @LancetOncology : Brilliant question answered by this RCT👉Any role of screening for malignant spinal cord compression & pre-emptive Rx in asymptomatic mCRPC #prostatecancer ? Answer is "NO". Congrats to @DearnaleyProf & team Free access: https://t.co/8r4yJOYCLA @OncoAlert pic.twitter.com/8oLIwKKOx1
— Neeraj Agarwal, MD, FASCO (@neerajaiims) March 12, 2022
M-A: Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy.
15 Mar, 2022 | 08:05h | UTC
RCT: Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer.
14 Mar, 2022 | 00:41h | UTC
GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer.
10 Mar, 2022 | 10:35h | UTC
RCT: Pain and health-related quality of life with olaparib vs. physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.
10 Mar, 2022 | 10:18h | UTCPain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Review: Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer.
10 Mar, 2022 | 10:02h | UTC
Multiparametric ultrasound vs. multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
7 Mar, 2022 | 00:04h | UTCMultiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study – The Lancet Oncology (link to abstract – $ for full-text)
News Release: Ultrasound scan can diagnose prostate cancer – Imperial College London
Commentary on Twitter
In a prospective confirmatory study comparing multiparametric US vs MRI for prostate cancer detection in 306 men with an abnormal PSA or DRE findings, US detected 4.3% fewer clinically significant cancers despite 11.1% more pts being referred for a biopsy: https://t.co/ZFkiUTFJ5Y
— NatureRevClinOncol (@NatRevClinOncol) March 3, 2022
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
(Epi)genetic predisposing factors found in one-third of children diagnosed with Wilms tumor.
3 Mar, 2022 | 08:10h | UTC
RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
18 Feb, 2022 | 08:47h | UTC
Commentary on Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022
Supportive care needs of men with prostate cancer: A systematic review of qualitative studies.
17 Feb, 2022 | 08:34h | UTC
M-A: Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma.
11 Feb, 2022 | 08:15h | UTC
M-A: Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma.
9 Feb, 2022 | 08:39h | UTC
M-A: Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials.
3 Feb, 2022 | 08:31h | UTC
Commentary on Twitter
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysishttps://t.co/cnLe3oxATE@ricautor @spsutkaMD @MRoupret @AndreaNecchi @pcvblack pic.twitter.com/EmeapD8O54
— European Urology (@EUplatinum) January 30, 2022
NCCN Guideline: Kidney Cancer.
2 Feb, 2022 | 08:30h | UTC
Meta-analysis: Androgen deprivation therapy, in addition to radiotherapy, is associated with improved metastasis-free survival in men with localized prostate cancer.
1 Feb, 2022 | 08:24h | UTCAndrogen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
Perspective | Ultrahypofractionated radiotherapy for localized prostate cancer: how far can we go?
28 Jan, 2022 | 08:09h | UTC
M-A: Late kidney effects of nephron-sparing vs. radical nephrectomy for Wilms Tumor.
27 Jan, 2022 | 09:22h | UTCLate Kidney Effects of Nephron-Sparing vs Radical Nephrectomy for Wilms Tumor: A Systematic Review and Meta-Analysis – The Journal of Urology (link to abstract – $ for full-text)
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
25 Jan, 2022 | 09:28h | UTC
M-A: BRCA1 and BRCA2 pathogenic variants and prostate cancer risk.
25 Jan, 2022 | 09:01h | UTC
Review: Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
25 Jan, 2022 | 08:59h | UTC
Review: Imaging of prostate cancer.
18 Jan, 2022 | 09:20h | UTCImaging of Prostate Cancer – Deutsches Ärzteblatt International
Related:
ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management
Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer
Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy
Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
16 Jan, 2022 | 22:41h | UTCCommentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet
Commentary from one of the authors on Twitter (thread – click for more)
Honored to be part of the recently published study in Nature Medicine on the global #AI competition PANDA as a member of the @Google team and an expert panel of 6 US and Canadian Uropathologists. Check out this thread for my 5 top takeaways 👇#pathology #PathTwitter
— Dr. Mahul Amin (@DrMahul) January 14, 2022